Lattice Biologics (Lattice Biologics) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2021)

View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lattice Biologics's long-term debt to total assests ratio for the quarter that ended in Jun. 2021 was 0.00.

Lattice Biologics's long-term debt to total assets ratio declined from Jun. 2020 (0.22) to Jun. 2021 (0.00). It may suggest that Lattice Biologics is progressively becoming less dependent on debt to grow their business.

Lattice Biologics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Lattice Biologics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics LT-Debt-to-Total-Asset Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.14

0.23

0.09

0.29

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.22	0.29	0.30	-	-

Lattice Biologics LT-Debt-to-Total-Asset Calculation

Lattice Biologics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2020 is calculated as

LT Debt to Total Assets (A: Sep. 2020 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2020 )	/	Total Assets (A: Sep. 2020 )
	=	0.888	/	3.018
	=	0.29

Lattice Biologics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2021 is calculated as

LT Debt to Total Assets (Q: Jun. 2021 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2021 )	/	Total Assets (Q: Jun. 2021 )
	=	0	/	0.606
	=

Lattice Biologics (OTCPK:LBLTF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lattice Biologics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (Lattice Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines